Genetic Expression and Prediction of Response to Neoadjuvant Docetaxel or Doxorubicin in Locally Advanced Breast Cancer

NCT00123929 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

250

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: docetaxel
DRUG: doxorubicin

Sponsor

Hospital San Carlos, Madrid

Collaborators

[object Object]